Therefore, a novel therapy with the combination of Sunitinib and anti-AR therapy could be developed to compensate for and cover each therapy’s unwanted side effects to better suppress RCC progression (summarized in Fig. 9b). This evidence concerns the gene AR and renal cell carcinoma.